Inclusion Criteria:

          -  Histologic diagnosis of renal cell carcinoma (any histology except medullary carcinoma
             or collecting duct carcinoma is acceptable) with radiologic or histologic evidence of
             metastatic disease.

          -  Prior treatment with up to one (and only one) anti-VEGF or VEGFR inhibitor (small
             molecule or antibody).

          -  Must have measurable disease as per Response Evaluation Criteria in Solid Tumors,
             version 1.1 (RECIST 1.1) criteria.

          -  Must be of age ≥ 18 years at time of informed consent.

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Karnofsky Performance Status ≥60. (The Karnofsky Performance Status Scale is an
             assessment tool for functional impairment. It can be used to compare effectiveness of
             different therapies and to assess the prognosis in individual patients. In most
             serious illnesses, the lower the Karnofsky score, the worse the likelihood of
             survival.)

          -  Most recent systemic therapy or most recent radiation therapy ≥ 2 weeks of first study
             drug dose.

          -  Recovery to baseline or < Grade 1 CTCAE v.4.03 from toxicities related to any prior
             treatments, unless AE(s) are clinically non-significant and/or stable on supportive
             therapy.

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 28 days prior to registration.

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Prior treatment for metastatic disease with >1 anti-VEGF/VEGFR inhibitor.

          -  Prior treatment with anti-PD/PD-L1/CTLA4/IDO antibody (for Cohort B patients only) or
             ESK981 (for Cohort A and Cohort B patients).

          -  Prior mTOR inhibitors or glutaminase inhibitors are allowed.

          -  Untreated brain metastases or spinal cord compression.

          -  Uncontrolled hypertension defined as blood pressure >150/90 despite at least 2
             anti-hypertensive medication(s) as assessed by 2 blood pressure readings taken at
             least 1 hour apart during screening.

          -  Major surgical procedure or significant traumatic injury within 6 weeks prior to study
             registration (> 6 weeks prior to registration is permitted as long as they have fully
             recovered from any such procedure).

          -  History of another primary malignancy except for: malignancy treated with curative
             intent and no known active disease for ≥2 years, adequately treated non-melanoma skin
             cancer without current evidence of active disease, adequately treated carcinoma in
             situ without current evidence of active disease, Gleason ≤6 prostate cancer.

          -  Angina, myocardial infarction symptomatic congestive heart failure, cerebrovascular
             accident, transient ischemic attack, arterial embolism, pulmonary embolism,
             percutaneous angioplasty or coronary arterial bypass surgery within the past 3 months.

          -  History of gastrointestinal perforation or fistula in the past 6 months, or while
             previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g.
             through surgical resection or repair).

          -  The patient has known hypersensitivity to gelatin or lactose monohydrate.

          -  The patient has received any investigational drug within 28 days prior to registration
             or 5 half-lives of the investigational drug, whichever is shorter.

          -  History of bleeding disorders (e.g. pulmonary hemorrhage, significant hemoptysis,
             menometrorrhagia not responding to hormonal treatment) ≤ 6 weeks before Cycle 1 Day1.

          -  The patient is on a chronic daily medication known to be a severe or moderate
             inhibitor or inducer by Micromedex of CYP1A2, CYP2C8, or CYP3A4 at registration.

          -  Systemic corticosteroids greater than the equivalent of 10 mg of prednisone or
             equivalent alternative steroid (except physiologic dose for adrenal replacement
             therapy) or other immunosuppressive agents (such as cyclosporine or methotrexate) and
             any other medications that could potentially impact the efficacy or safety of the
             study as judged by the treating investigator are NOT permitted from time of
             registration to subjects completing protocol therapy unless clinically indicated to
             manage adverse events or life threatening or serious conditions as determined by the
             treating investigator.

          -  Have any condition that, in the opinion of the investigator, would compromise the
             ability of the subject to meet or perform study requirements.